Zheng Quan Shi Bao Wang·2025-09-18 01:08Core Viewpoint - XuanZhu Biotech has passed the main board listing hearing of the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) as its sole sponsor [1] Group 1: Company Overview - The company is an innovation-driven Chinese biopharmaceutical firm with an internal R&D platform and a diversified pipeline [1] - As of September 10, 2025, the company has over ten drug assets actively under development, targeting diseases related to the digestive system, oncology, and NASH [1] Group 2: Key Products - Core products include KBP-3571 (for digestive system diseases), XZP-3287 (for breast cancer), and XZP-3621 (for non-small cell lung cancer), all of which have received NDA approval [1] - KBP-3571 has achieved sales of RMB 32.7 million since its commercialization up to March 31, 2025 [1] Group 3: Business Strategy - The company employs a dual-track approach of independent R&D and external licensing to rapidly bring candidate drugs to market [1]